4d Molecular Therapeutics Stock Net Asset
| FDMT Stock | USD 8.53 0.08 0.95% |
4D Molecular Therapeutics fundamentals help investors to digest information that contributes to 4D Molecular's financial success or failures. It also enables traders to predict the movement of FDMT Stock. The fundamental analysis module provides a way to measure 4D Molecular's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to 4D Molecular stock.
FDMT | Net Asset |
4D Molecular Therapeutics Company Net Asset Analysis
4D Molecular's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current 4D Molecular Net Asset | 339.89 M |
Most of 4D Molecular's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, 4D Molecular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
FDMT Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for 4D Molecular is extremely important. It helps to project a fair market value of FDMT Stock properly, considering its historical fundamentals such as Net Asset. Since 4D Molecular's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of 4D Molecular's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of 4D Molecular's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
FDMT Total Assets
Total Assets |
|
Based on the recorded statements, 4D Molecular Therapeutics has a Net Asset of 339.89 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
FDMT Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses 4D Molecular's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics of similar companies.4D Molecular is currently under evaluation in net asset category among its peers.
4D Molecular ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, 4D Molecular's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to 4D Molecular's managers, analysts, and investors.Environmental | Governance | Social |
4D Molecular Institutional Holders
Institutional Holdings refers to the ownership stake in 4D Molecular that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of 4D Molecular's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing 4D Molecular's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.5 M | Novo A/s | 2024-06-30 | 1.4 M | Redmile Group, Llc | 2024-06-30 | 1.1 M | Geode Capital Management, Llc | 2024-06-30 | 1.1 M | Fmr Inc | 2024-06-30 | 1 M | Eventide Asset Management, Llc | 2024-06-30 | 881.2 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 850.2 K | Casdin Capital, Llc | 2024-06-30 | 800 K | Healthcare Of Ontario Pension Plan Trust Fund | 2024-06-30 | 706 K | Ra Capital Management, Llc | 2024-06-30 | 5.1 M | Blackrock Inc | 2024-06-30 | 4.9 M |
FDMT Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (84.99 M) | ||||
| Shares Outstanding | 51.97 M | ||||
| Shares Owned By Insiders | 3.48 % | ||||
| Shares Owned By Institutions | 96.52 % | ||||
| Number Of Shares Shorted | 10.93 M | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 21.93 X | ||||
| Revenue | 20.72 M | ||||
| Gross Profit | (77.12 M) | ||||
| EBITDA | (107.12 M) | ||||
| Net Income | (100.84 M) | ||||
| Cash And Equivalents | 241.09 M | ||||
| Cash Per Share | 7.45 X | ||||
| Total Debt | 14.67 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 17.20 X | ||||
| Book Value Per Share | 11.33 X | ||||
| Cash Flow From Operations | (75.79 M) | ||||
| Short Ratio | 11.42 X | ||||
| Earnings Per Share | (2.24) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 50.0 | ||||
| Number Of Employees | 201 | ||||
| Beta | 2.76 | ||||
| Market Capitalization | 443.3 M | ||||
| Total Asset | 339.89 M | ||||
| Retained Earnings | (415.33 M) | ||||
| Working Capital | 277.64 M | ||||
| Net Asset | 339.89 M |
About 4D Molecular Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze 4D Molecular Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.